<<
>>

.. : . . ... . . . ., 2004. .. . 2000; 1: 18-21. .. :   .

Consilium Medicum 2008; 10(1). .., .., - .. . . , .

, . 2006; 8(2): 38-39. .. - . , . . . 2005; 7: 233-236. .., .., .. . : , 2007: 77-83. . . : . .: , 2006. .. IV . . . 2003; 48(7): 5-11. .., .. . Consilium Medicum 2007; 9(1): 20-28. Bauhofer A., Celik I., Plaul U. et at. Effects of G-CSF and antibiotic prophylaxis in a 2x2 factorial design on outcome in septic rats. In- flamm. Res. 2004; 53: 126-129. Bauhofer A., Huftel M., Lorenz W. efal. Differential effects of antibiotics in combination with G-CSF on survival and polymorphonuclear granulocyte cell functions in septic rats. BMC Infect. Dis. 2008; 8: 55.

Bauhofer A., Torossian A., Lorenz W. ef al. Dependence of positive effects of granulocyte colony-stimulating factor on the anti-

biotic regimen: evaluation in rats with polymicrobial peritonitis. World J. Surg. 2004; 28: 834-844. Brooks B.M., Harf C.A., Coleman J.W. Differential effects of beta-lactams on human IFN-gamma activity. J. Antimicrob. Che- mother. 2005; 56: 1122-1125. Bush ., Heep M., Macielag M.J., Noel G.J. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first an- ti-MRSA beta-lactam to demonstrate clinical efficacy. Exp. Opin. Invest. Drugs 2007; 16:419-429. ѳ X., Song Y., Zeng F. ef al. Ceftiofur impairs pro-inflammatory cytokine secretion through the inhibition of the activation of NF-kappaB and Biochem. Biophys. Res. Commun. 2008; 372: 73-77. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and Iine- zolid. Infect. Dis. Clin. N. Am. 2003; 17: 479501. Endimiani A., Perez F., Bonomo R.A. Ce-

fepime: a reappraisal in an era of increasing antimicrobial resistance. Exp. Rev. Antiinfect. Ther. 2008; 6: 805-824. Fallon R.M., Kuti J.L., Doern G.V. et al. Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children. Paediatr. Drugs 2008; 10: 329-335. FieflaA., Bersani C., Berfolefti R. efal. In vitro and ex vivo enhancement of nonspecific phagocytosis by cefodizime. Chemotherapy 1988; 34: 430-436. Fort! I.N. Review of oral cephalosporins. Basis for a rational choice. Medicina (B Aires) 1994; 54: 439-458. Giske C.G., Sundsfjord A.S., Kahlmefer G. ef

al. Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J. Antimicrob. Chemother. 2009; 63: 1-4. Gusfaferro C.A., Steckelberg J.M. Cephalosporin antimicrobial agents and related compounds. Mayo Clin. Proc. 1991; 66: 10641073.

Hamilton-Miller J.M. Immunopharmacology of antibiotics: direct and indirect immuno-

r

modulation of defence mechanisms. J. Chemother. 2001; 13: 107-111. Igea J.M., Fraj J., Davila I. et al. Allergy to cefazolin: study of in vivo cross reactivity with other betalactams. Ann. Allergy. 1992; 68: 515-519. Ikawa K., Nomura K., Morikawa N. et al.

Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients. J. Infect. Chemother. 2008; 14: 130-136. Jones M.E. In vitro profile of a new beta- lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 2007; 13: 17-24. Kenny M.T., Balistreri F.J., Forney H.L. beta-Lactam antibiotic modulation of murine neutrophil cytokinesis. Immunopharmacol. Immunotoxicol. 1992; 14: 797-811. Koomanachai P., Crandon J.L., Kuti J.L., Nico- lau D.P. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Int. J. Antimicrob. Agents 2008; 33: 348-353. Labro M.T. Immunological evaluation of cefodizime: a unique molecule among cephalosporins. Infection 1992; 20: 45-47. Labro M.T. Interference of Antibacterial Agents with Phagocyte Functions: Immu- nomodulation or Immuno-Fairy Tales? Clin. Microbiol. Rev. 2000; 13: 615-650. Labro M.T., Amit N., Babin-Chevaye C., Hakim J. Cefodizime (HR 221) potentiation of human neutrophil oxygen-independent bactericidal activity. J. Antimicrob. Chemother. 1987; 19: 331-341. Labro M.T., Babin-Chevaye C., Hakim J. Effects of cefotaxime and cefodizime on human granulocyte functions in vitro. J. Antimicrob. Chemother. 1986; 18: 233-236. Lebrec H., Kerdine S., Gaspard I., Pallardy M. Th(l)/Th(2) responses to drugs. Toxicology 2001; 158: 25-29. Limbert M. Effect of cefodizime on the immune system: in vitro studies. Immun. In- fekt. 1986; 14: 28-29. Lingaas E., Midtvedt T. The influence of ce- foperazone, cefotaxime, ceftazidime and az-

treonam on phagocytosis by human neutrophils in vitro. J. Antimicrob. Chemother. 1989; 23: 701-710. MacGowan A.P., Bowker K.E. Continuous infusion of beta-lactam antibiotics. Clin. Pharmacokinet. 1998; 35: 391-402. Mallmann P., Bruhl P., Dagrosa E.E., Reeves A. Effect of cefodizime on parameters of cell-mediated immunity in vitro. Arzneimit- telforschung. 1992; 42: 567-570. Oishi K., Matsumoto K., Yamamoto M. et al. Stimulatory effect of cefodizime on macrophage-mediated phagocytosis. J. Antibiot. (Tokyo) 1989; 42: 989-992. Parnham M.J. Antibiotics, inflammation and its resolution: an overview. In: Antibiotics as anti-inflammatory and immunomodulatory agents. Ed. by B.K. Rubin, J. Tamaoki. Basel: Birk Verlag, 2004: 27-48. Rodriguez A.B., Barriga C., De la Fuente M. Stimulation of phagocytic processes and antibody-dependent cellular cytotoxicity of human neutrophils by cefmetazole. Microbiol. Immunol. 1991; 35: 545-556. Rodriguez A.B., Barriga C., De la Fuente M. Mechanisms of action involved in the chemoattractant activity of three /J-lactamic antibiotics upon human neutrophils. Bio- chem. Pharmacol. 1991; 41: 931-936. Rodriguez A.B., Hernanz A., De la Fuente M. Effect of three /-lactam antibiotics on ascorbate content, phagocytic activity and superoxide anion production in human neutrophils. Cell Physiol. Biochem. 1991; 1:170-176. Roszkowski W., Fi.L., Roszkowski K. et al. Antibiotics and immunomodulation: effects of cefotaxime, amikacin, mezlocillin, piperacillin and clindamycin. Med. Microbiol. Immunol. 1985; 173: 279-289. Rouveix B., Chau F. Action of cephalosporins on T lymphocytes: the role of mediators. Pathol. Biol. (Paris) 1987; 35: 1450-1453. Saeed S.A., Bazza M., Zaman M., Ryatt K.S. Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad. Med J. 2000; 76: 577-579. Scheffer J., Koller J., Cullmann W., Konig

W. Effects of cefaclor, cefetamet and RO 40-6890 on inflammatory response of human granulocytes. J. Antimicrob. Chemother. 1992; 30: 57-66. Schmidt-loanas M., de Roux A., Lode H. New

antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr. Opin. Crit. Care. 2005; 11: 481-486. Sevillano D., Aguilar L., Alou L. etal. Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics. PLoS ONE. 2008; 3: e3846. Shin W.S., Min C.K., Kim Y.R. et al. In vitro effects of cefodizime on leukocyte functions and colony formation from granulocyte- monocyte progenitors. In-vitro effects of cefodizime on leukocyte functions and colony formation from granulocyte-monocyte progenitors. J. Antimicrob. Chemother. 1996; 37: 93-103. Simon D.M., Koenig G., Trenholme G.M.

Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli. J. Infect. Dis. 1991; 164: 800-802. Thompson R.L. Cephalosporin, carbapen- em, and monobactam antibiotics. Mayo Clin. Proc. 1987; 62: 821-834. Tullio V., Cuffini A.M., CavalloR. etal. Effect of ceftriaxone on the phagocytosis and intracellular killing of Staphylococcus aureus by human macrophages. J. Chemother. 1994; 6:177-183. Wang M., Dong Ft.J., Gong Z.H. Effects of beta-lactam antibiotics on development of tolerance and dependence to morphine. Yao Xue Xue Bao. 2008; 43: 1094-1098. Whitman C.B., Joseph J.M., Sjoholm L.O. Cephalosporin-induced leukopenia following rechallenge with cefoxitin. Ann. Phar- macother. 2008; 42: 1327-1332.

<< | >>
: .. , .. , .. . 2012. 2012

:

- - - -
- - - - - - - - - - - - - -